ALCHEMIST
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Anjali Rohatgi, MD PhD

NRG Oncology Semi-Annual Meeting
July 2022
Disclosures: None
Accruing ALCHEMIST Trials

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

E4512: Crizotinib in Treating Patients with Stage IB-IIIA NSCLC that has been Removed by Surgery and ALK Fusion
# ALCHEMIST Accrual (As of 7/1/2022)

<table>
<thead>
<tr>
<th>Study</th>
<th># Registered</th>
<th># Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Sites open for A151216</td>
<td>1281</td>
<td></td>
</tr>
<tr>
<td>A151216 (Screening)</td>
<td>6589</td>
<td>8300</td>
</tr>
<tr>
<td>A081105 (EGFR) closed 1/20/21</td>
<td>390</td>
<td>450</td>
</tr>
<tr>
<td>E4512 (ALK)</td>
<td>136</td>
<td>168</td>
</tr>
<tr>
<td>A081801 (Chemo-IO)</td>
<td>254</td>
<td>1210</td>
</tr>
<tr>
<td>EA5142 (ANVIL), closed 10/1/19</td>
<td>935</td>
<td>903</td>
</tr>
</tbody>
</table>
ALCHEMIST Accrual by Quarter

Number of Enrollments (log scale)

Quarter


Screening

ALK

Chemo-IO

Screening

ALK

Chemo-IO

A151216, Total: 6510/8300
A081105, Total: 390/450 (Closed to accrual 1/20/2021)
E4512, Total: 134/168
EA5142, Total: 935/903 (Closed to accrual 10/1/2019)
A081801, Total: 227/1210

as of 4/20/2022
Updated Study Design

- Surgical resection (R0) and eligibility criteria consistent with ongoing ALCHEMIST trials

Enrollment on A151216 → Randomization

- Platinum doublet* (x8 doses = 16 cycles)
- Pembrolizumab** (to complete total 8 doses = 16 cycles)

+/- PORT

- Pembrolizumab**

**Each experimental arm includes a total of 8 doses of Q6 wks pembrolizumab

*Acceptable regimens
Cisplatin (or carbo) pemetrexed
Cisplatin gemcitabine
Carboplatin paclitaxel
Grant/Sponsor Acknowledgements

The ALCHEMIST studies are being coordinated by the Alliance for Clinical Trials in Oncology and the ECOG-ACRIN Cancer Research Group, members of the NCI-sponsored National Clinical Trials Network (NCTN), as part of the institute’s national strategy for precision medicine.

NCT02194738 (Screening A151216), NCT02193282 (EGFR A081105), NCT02201992 (ALK E4512), NCT02595944 (ANVIL, EA5142), NCT04267848 (Chemo-IO A081801)